Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Brentuximab Vedotin · Adcetris, CAC10-VCMMAE

Antibody-drug conjugate · Cytotoxic, directed at CD30 (TNFRSF8) · developed by Seattle Genetics

Approved FDA, Aug 2011

What is Brentuximab Vedotin?

Brentuximab vedotin is an antibody-drug conjugate in which a chimeric IgG1 antibody binds CD30, and the microtubule-disrupting agent MMAE is attached through a cleavable linker. After binding and internalization by CD30-expressing cells, MMAE is released and disrupts microtubules, causing cell cycle arrest and apoptosis. It is studied in diffuse large B-cell lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Adcetris, CAC10-VCMMAE, SGN-35
Drug type
Antibody-drug conjugate
Targets
CD30 (TNFRSF8)
Mechanism
Cytotoxic, directed at CD30 (TNFRSF8)
Pathways
CD30-CD30L signaling affecting cell survival and proliferation, microtubule disruption, cell cycle arrest and apoptosis, antibody-dependent cellular phagocytosis
Therapy area
Oncology
Developer
Seattle Genetics
In trials of
PFE
FDA status
Approved as Adcetris (August 19, 2011), BLA125388 · FDA label
UNII
7XL5ISS668

✅ FDA-approved uses

From the indications section of the FDA label (version of Nov 11, 2025). Read the full label for the exact wording, limitations and safety information.

Conditions studied

Diffuse Large B-cell Lymphoma

Other drugs acting on TNFRSF8

Sources

Updated Oct 25, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.